Danielle Novetsky Friedman1, Joanne F Chou2, Kevin C Oeffinger1,3, Ruth A Kleinerman4, Jennifer S Ford5, Charles A Sklar1, Yuelin Li2, Mary S McCabe6, Leslie L Robison7, Brian P Marr8, David H Abramson8, Ira J Dunkel1. 1. Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York. 2. Department of Epidemiology-Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York. 3. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. 4. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, Maryland. 5. Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York. 6. Clinical Director, Survivorship Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 7. Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee. 8. Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Abstract
BACKGROUND: Limited data are available regarding long-term morbidity in adult survivors of retinoblastoma (Rb). METHODS: The Retinoblastoma Survivor Study is a retrospective cohort of adult survivors of Rb diagnosed between 1932 and 1994. Participants completed a comprehensive questionnaire adapted from the Childhood Cancer Survivor Study surveys. Chronic conditions were classified using the National Cancer Institute's Common Terminology Criteria for Adverse Events (version 4.03). Multivariate Poisson regression was used to compare survivors of Rb with 2377 non-Rb controls, consisting of the Childhood Cancer Survivor Study sibling cohort and survivors with bilateral versus unilateral disease. RESULTS: Survivors of Rb (53.6% with bilateral disease) and non-Rb controls had a mean age of 43.3 years (standard deviation, 11 years) and 37.6 years (SD, 8.6 years), respectively, at the time of study enrollment. At a median follow-up of 42 years (range, 15-75 years), 86.6% of survivors of Rb had at least 1 condition and 71.1% had a severe/life-threatening (grade 3-4) condition. The adjusted relative risk (RR) of a chronic condition in survivors compared with non-Rb controls was 1.4 (95% confidence interval [95% CI], 1.3-1.4; P<.01); for a grade 3 to 4 condition, the RR was 7.6 (95% CI, 6.4-8.9; P<.01). Survivors were at an excess risk regardless of laterality. After stratifying by laterality and excluding ocular conditions and second malignant neoplasms (SMNs), only those with bilateral disease were found to be at an increased risk of any nonocular, non-SMN condition (RR, 1.2; 95% CI, 1.1-1.2) and for grade 3 to 4 nonocular, non-SMN conditions (RR, 1.7; 95% CI, 1.2-2.5). CONCLUSIONS: Survivors of Rb have an increased risk of chronic conditions compared with non-Rb controls. After excluding ocular conditions and SMNs, this excess risk was found to persist only for those with bilateral disease. Cancer 2016;122:773-781.
BACKGROUND: Limited data are available regarding long-term morbidity in adult survivors of retinoblastoma (Rb). METHODS: The Retinoblastoma Survivor Study is a retrospective cohort of adult survivors of Rb diagnosed between 1932 and 1994. Participants completed a comprehensive questionnaire adapted from the Childhood Cancer Survivor Study surveys. Chronic conditions were classified using the National Cancer Institute's Common Terminology Criteria for Adverse Events (version 4.03). Multivariate Poisson regression was used to compare survivors of Rb with 2377 non-Rb controls, consisting of the Childhood Cancer Survivor Study sibling cohort and survivors with bilateral versus unilateral disease. RESULTS: Survivors of Rb (53.6% with bilateral disease) and non-Rb controls had a mean age of 43.3 years (standard deviation, 11 years) and 37.6 years (SD, 8.6 years), respectively, at the time of study enrollment. At a median follow-up of 42 years (range, 15-75 years), 86.6% of survivors of Rb had at least 1 condition and 71.1% had a severe/life-threatening (grade 3-4) condition. The adjusted relative risk (RR) of a chronic condition in survivors compared with non-Rb controls was 1.4 (95% confidence interval [95% CI], 1.3-1.4; P<.01); for a grade 3 to 4 condition, the RR was 7.6 (95% CI, 6.4-8.9; P<.01). Survivors were at an excess risk regardless of laterality. After stratifying by laterality and excluding ocular conditions and second malignant neoplasms (SMNs), only those with bilateral disease were found to be at an increased risk of any nonocular, non-SMN condition (RR, 1.2; 95% CI, 1.1-1.2) and for grade 3 to 4 nonocular, non-SMN conditions (RR, 1.7; 95% CI, 1.2-2.5). CONCLUSIONS: Survivors of Rb have an increased risk of chronic conditions compared with non-Rb controls. After excluding ocular conditions and SMNs, this excess risk was found to persist only for those with bilateral disease. Cancer 2016;122:773-781.
Authors: Wendy M Leisenring; Ann C Mertens; Gregory T Armstrong; Marilyn A Stovall; Joseph P Neglia; Jennifer Q Lanctot; John D Boice; John A Whitton; Yutaka Yasui Journal: J Clin Oncol Date: 2009-04-13 Impact factor: 44.544
Authors: Gregory T Armstrong; Toana Kawashima; Wendy Leisenring; Kayla Stratton; Marilyn Stovall; Melissa M Hudson; Charles A Sklar; Leslie L Robison; Kevin C Oeffinger Journal: J Clin Oncol Date: 2014-03-17 Impact factor: 44.544
Authors: Corina S Rueegg; Micol E Gianinazzi; Johannes Rischewski; Maja Beck Popovic; Nicolas X von der Weid; Gisela Michel; Claudia E Kuehni Journal: J Cancer Surviv Date: 2013-06-20 Impact factor: 4.442
Authors: Leslie L Robison; Ann C Mertens; John D Boice; Norman E Breslow; Sarah S Donaldson; Daniel M Green; Frederic P Li; Anna T Meadows; John J Mulvihill; Joseph P Neglia; Mark E Nesbit; Roger J Packer; John D Potter; Charles A Sklar; Malcolm A Smith; Marilyn Stovall; Louise C Strong; Yutaka Yasui; Lonnie K Zeltzer Journal: Med Pediatr Oncol Date: 2002-04
Authors: Melissa M Hudson; Ann C Mertens; Yutaka Yasui; Wendy Hobbie; Hegang Chen; James G Gurney; Mark Yeazel; Christopher J Recklitis; Neyssa Marina; Leslie R Robison; Kevin C Oeffinger Journal: JAMA Date: 2003-09-24 Impact factor: 157.335
Authors: Negar Omidakhsh; Arupa Ganguly; Greta R Bunin; Ondine S von Ehrenstein; Beate Ritz; Julia E Heck Journal: Am J Ophthalmol Date: 2017-01-26 Impact factor: 5.258
Authors: Smita C Banerjee; Elaine Pottenger; Mary Petriccione; Joanne F Chou; Jennifer S Ford; Charles A Sklar; Leslie L Robison; Ruth A Kleinerman; Kevin C Oeffinger; Jasmine H Francis; David H Abramson; Ira J Dunkel; Danielle Novetsky Friedman Journal: Palliat Support Care Date: 2020-06
Authors: Danielle Novetsky Friedman; Joanne F Chou; Jasmine H Francis; Charles A Sklar; Yuelin Li; Mary McCabe; Leslie L Robison; Ruth A Kleinerman; Kevin C Oeffinger; David H Abramson; Ira J Dunkel; Jennifer S Ford Journal: JAMA Ophthalmol Date: 2018-06-01 Impact factor: 7.389
Authors: Joanne F Chou; Jennifer S Ford; Ruth A Kleinerman; David H Abramson; Jasmine H Francis; Charles A Sklar; Kevin C Oeffinger; Leslie L Robison; Ira J Dunkel; Danielle Novetsky Friedman Journal: Pediatr Blood Cancer Date: 2021-01-26 Impact factor: 3.167
Authors: Sruti S Akella; Jasmine H Francis; Andrea Knezevic; Irina Ostrovnaya; Y Pierre Gobin; Danielle Friedman; Edith Guarini; Lindsey Eibeler; Federica Catalanotti; David H Abramson Journal: PLoS One Date: 2018-05-07 Impact factor: 3.240
Authors: Nina Streefkerk; Wim J E Tissing; Margriet van der Heiden-van der Loo; Elizabeth A M Lieke Feijen; Eline van Dulmen-den Broeder; Jacqueline J Loonen; Helena J H van der Pal; Cécile M Ronckers; Hanneke M van Santen; Marleen H van den Berg; Renée L Mulder; Joke C Korevaar; Leontine C M Kremer Journal: J Cancer Surviv Date: 2020-05-03 Impact factor: 4.442